Biomarker profi les in asthma with high vs low airway reversibility and poor disease control

Chest

Volumn 148, Issue 6, 2015, Pages 1489-1496

  Busse, William W ^a   Holgate, Stephen T ^b   Wenzel, Sally W ^c   Klekotka, Paul ^d   Chon, Yun ^d   Feng, Jing Yuan ^d   Ingenito, Edward P ^d   Nirula, Ajay ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRONCHODILATING AGENT; IMMUNOGLOBULIN E; NITRIC OXIDE; GLUCOCORTICOID; PROSTAGLANDIN D2;

ADULT; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ATOPY; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE CONTROL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HIGH AIRWAY REVERSIBILITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOW AIRWAY REVERSIBILITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TH2 CELL; ANTAGONISTS AND INHIBITORS; BLOOD; BREATH ANALYSIS; DRUG EFFECTS; DRUG MONITORING; EOSINOPHIL; IMMUNOLOGY; LEUKOCYTE COUNT; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; SEVERITY OF ILLNESS INDEX; STATISTICS; TREATMENT OUTCOME;

ADULT; ASTHMA; BIOMARKERS; BREATH TESTS; BRONCHODILATOR AGENTS; DRUG MONITORING; EOSINOPHILS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN E; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NITRIC OXIDE; PROSTAGLANDIN D2; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TH2 CELLS; TREATMENT OUTCOME;

EID: 84949057559     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2457     Document Type: Article

References (13)

1. Moore WC, Meyers DA, Wenzel SE, et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma pheno-types using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315-323.
2. Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol. 2014;133(5):1280-1288.
3. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-224.
4. Moore WC, Hastie AT, Li X, et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phe-notypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557-1563.e5.
5. Braiser AR, Victor S, Ju H, et al. Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. Clin Transl Sci. 2010;3(4):147-157.
6. Amgen Inc. AMG 853 phase 2 study in subjects with inadequately controlled asthma. NCT01018550. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2009. https://clinicaltrials.gov/ct2/show/NCT01018550. Updated May 19, 2011.
7. Amgen Inc. A study to evaluate the dosing of AMG 827 for subjects with inadequately controlled asthma. NCT01199289. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2010. https://clinicaltrials.gov/ct2/show/NCT01199289. Updated April 28, 2015.
8. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdf. Accessed August 29, 2014.
9. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma: full report 2007. National Heart, Lung, and Blood Institute website. https://www.nhlbi.nih. gov/files/docs/guidelines/asthgdln.pdf. Accessed August 29, 2014.
10. Dweik RA, Boggs PB, Erzurum SC, et al; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615.
11. Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil counts is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol. 2014;113(1):19-24. doi:10.1016/janal.2014:04.001.
12. de Jongste JC. Yes to NO: the first studies on exhaled nitric oxide-driven asthma treatment. Eur Respir J. 2005;26(3):379-381.
13. Smits HH, Grünberg K, Derijk RH, Sterk PJ, Hiemstra PS. Cytokine release and its modulation by dexamethasone in whole blood following exercise. Clin Exp Immunol. 1998;111(2):463-468.